Horizon Therapeutics Publ...

116.30
0.00 (0.00%)
At close: Jan 16, 2025, 9:00 PM

Horizon Therapeutics Public Statistics

Share Statistics

Horizon Therapeutics Public has 228.74M shares outstanding. The number of shares has increased by -0.39% in one year.

Shares Outstanding 228.74M
Shares Change (YoY) -0.39%
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating 211.06M
Failed to Deliver (FTD) Shares -
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is -, so null% of the outstanding shares have been sold short.

Short Interest -
Short % of Shares Out null%
Short % of Float null%
Short Ratio (days to cover) null

Valuation Ratios

The PE ratio is undefined and the forward PE ratio is null. Horizon Therapeutics Public's PEG ratio is undefined.

PE Ratio undefined
Forward PE n/a
PS Ratio 7.18
Forward PS null
PB Ratio 5.14
P/FCF Ratio undefined
PEG Ratio undefined
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Horizon Therapeutics Public.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.85, with a Debt / Equity ratio of undefined.

Current Ratio 3.85
Quick Ratio 3.67
Debt / Equity undefined
Debt / EBITDA -
Debt / FCF -
Interest Coverage undefined

Financial Efficiency

Return on Equity is 0.1% and Return on Invested Capital is 8%.

Return on Equity 0.1%
Return on Assets 0.06%
Return on Invested Capital 8%
Revenue Per Employee $1.66M
Profits Per Employee $238.12K
Employee Count 2,190
Asset Turnover 0.4
Inventory Turnover 5.43

Taxes

Income Tax 5.45M
Effective Tax Rate 0.01%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 1.01, so Horizon Therapeutics Public's price volatility has been higher than the market average.

Beta 1.01
52-Week Price Change null%
50-Day Moving Average 110.78
200-Day Moving Average 108.29
Relative Strength Index (RSI) 83.96
Average Volume (20 Days) -

Income Statement

In the last 12 months, Horizon Therapeutics Public had revenue of 3.63B and earned 521.48M in profits. Earnings per share was 2.28.

Revenue 3.63B
Gross Profit 2.71B
Operating Income 617.41M
Net Income 521.48M
EBITDA 1.11B
EBIT 617.41M
Earnings Per Share (EPS) 2.28
Full Income Statement

Balance Sheet

The company has 2.35B in cash and 2.56B in debt, giving a net cash position of -210M.

Cash & Cash Equivalents 2.35B
Total Debt 2.56B
Net Cash -210M
Retained Earnings 590.01M
Total Assets 9.3B
Working Capital 3B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.26B and capital expenditures -126.28M, giving a free cash flow of 1.13B.

Operating Cash Flow 1.26B
Capital Expenditures -126.28M
Free Cash Flow 1.13B
FCF Per Share 4.94
Full Cash Flow Statement

Margins

Gross margin is 74.64%, with operating and profit margins of 17.01% and 14.37%.

Gross Margin 74.64%
Operating Margin 17.01%
Pretax Margin 14.52%
Profit Margin 14.37%
EBITDA Margin 30.71%
EBIT Margin 17.01%
FCF Margin 31.18%

Dividends & Yields

HZNP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

Currently there are no analyst rating for HZNP.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Scores

Altman Z-Score 5.09
Piotroski F-Score 8